Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02138929 · ClinicalTrials.gov registry record · Phase 1
LDE225 + Everolimus in Advanced Gastroesophageal Adenocarcinoma
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT02138929: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT02138929 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02138929, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the highest tolerable dose of LDE225 that can be given in combination with everolimus to patients with esophageal or GEJ cancer. The safety of the drug combination will also be studied.
Interventions
- DRUG Everolimus
- DRUG LDE 225
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2014-11-10 |
| Est. Completion | 2020-06-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02138929
The ClinicalTrials.gov registry entry for NCT02138929 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Everolimus is the first listed.
NCT02138929 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02138929 about?
NCT02138929 is a clinical study titled "LDE225 + Everolimus in Advanced Gastroesophageal Adenocarcinoma". The goal of this clinical research study is to find the highest tolerable dose of LDE225 that can be given in combination with everolimus to patients with esophageal or GEJ cancer. The safety of the drug combination will also be studied.
What is the current status of trial NCT02138929?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2014-11-10. Estimated completion is 2020-06-08.
What interventions are being tested in trial NCT02138929?
The interventions under investigation include: Everolimus (DRUG), LDE 225 (DRUG).
Who is sponsoring clinical trial NCT02138929?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.